Petracca A, Nisita C, McNair D, Melis G, Guerani G, Cassano G B
Institute of Clinical Psychiatry, University of Pisa, Italy.
J Clin Psychiatry. 1990 Sep;51 Suppl:31-9.
The authors reviewed pharmacologic treatment of generalized anxiety disorder (GAD), particularly treatment with benzodiazepine agents, and compared the antianxiety effects and dependence risks of these agents with those of nonGABAergic compounds such as buspirone--a new psychotropic drug--in the treatment of chronic anxiety. Forty outpatients who met DSM-III criteria for GAD were randomly assigned to double-blind treatment with buspirone or lorazepam. After 8 weeks, treatment was abruptly stopped and withdrawal reactions were evaluated at Weeks 9 and 10. After 3 to 4 weeks, buspirone's efficacy in treating GAD symptomatology was found to be comparable with lorazepam's, except for sleep disturbances, which were minimally affected by buspirone. After treatment was discontinued, buspirone-treated patients were free from withdrawal symptoms, while the symptoms of lorazepam-treated patients worsened at Week 9.
作者回顾了广泛性焦虑症（GAD）的药物治疗，特别是苯二氮䓬类药物的治疗，并比较了这些药物与非GABA能化合物（如丁螺环酮——一种新型精神药物）在治疗慢性焦虑时的抗焦虑作用和依赖风险。40名符合DSM-III广泛性焦虑症标准的门诊患者被随机分配接受丁螺环酮或劳拉西泮的双盲治疗。8周后，突然停药，并在第9周和第10周评估戒断反应。3至4周后，发现丁螺环酮治疗广泛性焦虑症症状的疗效与劳拉西泮相当，但睡眠障碍除外，丁螺环酮对睡眠障碍影响极小。停药后，接受丁螺环酮治疗的患者没有出现戒断症状，而接受劳拉西泮治疗的患者症状在第9周恶化。
